Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Zh Nevrol Psikhiatr Im S S Korsakova ; 124(4. Vyp. 2): 33-40, 2024.
Artigo em Russo | MEDLINE | ID: mdl-38696149

RESUMO

OBJECTIVE: To study the severity and localization of dilated perivascular spaces (DPVS), the levels of protein markers of amyloidosis and neurodegeneration in the cerebrospinal fluid (CSF) at different daily blood pressure (BP) profiles in patients with Alzheimer's disease (AD) and other types of cognitive impairment. MATERIAL AND METHODS: A total of 119 people, aged 53 to 92 years, including 55 patients with AD, 27 patients with vascular cognitive disorders (VCD), 19 patients with frontotemporal degeneration (FTD). All patients underwent BP monitoring for 24 hours using a standard oscillometric measurement method, lumbar puncture to assess Aß-42 and Aß-40 amyloid protein, total and phosphorylated tau protein in the CSF, magnetic resonance imaging tomography of the brain with subsequent assessment of the severity of expansion and localization of DPVS according to the G.M. Potter scale. RESULTS: In 58.3% of patients with AD, there is no adequate reduction in BP at night in comparison with patients with VCD (p<0.05). A significant degree of expansion of the DPVS turned out to be most typical for patients with AD: grade 3 was detected in 45.7% of patients, and the maximum, grade 4, was detected in 13.4%. At the same time, DPVSs were significantly more often detected in the group of subjects with insufficient reduction in diastolic BP (DBP) at night. A strong inverse correlation was established between the level of Aß-42 in the CSF and the variability of DBP at night (r= -0.92; p<0.05). The decrease in the level of Aß-42 in AD, especially at the prodromal stage, is directly related to the low variability of DBP at night, which is more characteristic of an insufficient decrease or increase in BP during night sleep. CONCLUSION: Patients with AD were characterized by an insufficient decrease in BP at night, which is associated with the severity and degree of maximum expansion of the DPVS. A decrease in the level of Aß-42 amyloid protein in the CSF strongly correlates with the variability of DBP at night.


Assuntos
Doença de Alzheimer , Peptídeos beta-Amiloides , Hipertensão , Proteínas tau , Humanos , Doença de Alzheimer/líquido cefalorraquidiano , Doença de Alzheimer/diagnóstico por imagem , Idoso , Feminino , Masculino , Pessoa de Meia-Idade , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Hipertensão/complicações , Hipertensão/líquido cefalorraquidiano , Idoso de 80 Anos ou mais , Proteínas tau/líquido cefalorraquidiano , Imageamento por Ressonância Magnética , Sistema Glinfático/diagnóstico por imagem , Pressão Sanguínea/fisiologia , Fragmentos de Peptídeos/líquido cefalorraquidiano , Demência Vascular/líquido cefalorraquidiano , Demência Vascular/diagnóstico por imagem , Biomarcadores/líquido cefalorraquidiano , Encéfalo/diagnóstico por imagem , Encéfalo/patologia
2.
Dement Geriatr Cogn Disord ; 34(1): 61-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22922641

RESUMO

BACKGROUND/AIMS: Demyelination and axonal degeneration are the hallmarks of established white matter lesions (WML). The neurochemistry of ongoing WML is only partially known. We explored cerebrospinal fluid (CSF) substances as markers of brain tissue damage in relation to progression of WML rated on magnetic resonance imaging. METHODS: CSF from elderly individuals with WML was analyzed for amyloid markers, total τ, hyperphosphorylated τ, neurofilament protein light subunit, sulfatide and CSF/serum-albumin ratio. After 3 years, a follow-up magnetic resonance imaging was performed. Progression of WML was rated using the Rotterdam Progression Scale (RPS). RESULTS: 37 subjects (age 73.6 ± 4.6 years) were included. Subjects with more pronounced progression (RPS > 2; n = 15) had lower mean sulfatide concentration at baseline as compared to subjects with no or minimal progression (RPS 0-2; n = 22) according to univariate analyses (p = 0.009). Sulfatide was the only biomarker that predicted the RPS score according to regression analysis, explaining 18.9% of the total variance (r = 0.38, p = 0.015). CONCLUSION: The correlation of CSF sulfatide levels and RPS scores may reflect a remyelination response to the demyelination process associated with WML. Furthermore, the results strengthen the notion that WML pathology is different from that of Alzheimer's disease.


Assuntos
Encéfalo/patologia , Sulfoglicoesfingolipídeos/líquido cefalorraquidiano , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/líquido cefalorraquidiano , Doença de Alzheimer/psicologia , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Biomarcadores , Demência Vascular/líquido cefalorraquidiano , Demência Vascular/psicologia , Doenças Desmielinizantes/patologia , Doenças Desmielinizantes/psicologia , Progressão da Doença , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Leucoaraiose/líquido cefalorraquidiano , Leucoaraiose/psicologia , Modelos Lineares , Imageamento por Ressonância Magnética , Masculino , Degeneração Neural/patologia , Degeneração Neural/psicologia , Países Baixos/epidemiologia , Testes Neuropsicológicos , Valor Preditivo dos Testes , Fatores Socioeconômicos , Proteínas tau/líquido cefalorraquidiano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA